AbbVie
Prezzo: 227.73Società e modello di business
AbbVie is a global biopharmaceutical company focused on developing and delivering advanced therapies for complex diseases. Its core products include immunology, oncology, and neuroscience treatments, with key revenue sources stemming from blockbuster drugs such as Humira and newer therapies like Rinvoq and Skyrizi. The company operates primarily in the healthcare sector, emphasizing research and development to address unmet medical needs.
Profilo di investimento
AbbVie presents a balanced investment profile, appealing to investors seeking both growth and income through its solid dividend yield. The company's consistent revenue growth and established market presence suggest stability, while ongoing innovation in its product pipeline indicates potential for future expansion. This makes it suitable for investors with a medium to long-term horizon.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 2.04 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -9.7% ↓
- Sorpresa EPS
- 2.3% in linea
- Volatilità 20g
- 1.3% stabile
- Rendimento dividendo
- 3.7% moderato ultima data ex-dividendo: 2026-04-15
Impatto della previsione
negativoTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-01 02:55 | Compra | Mantieni | Stable dividends, but mixed momentum and market signals. |
| 2026-05-24 02:30 | Mantieni | Compra | Solid fundamentals, but mixed momentum signals. |
| 2026-05-08 15:02 | — | Mantieni | Weak momentum and high risk overshadow dividend appeal. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-15 12:20 | Evercore ISI | Target abbassato | 236 → 235 | 212.045 |
| 2026-05-14 10:56 | Piper Sandler | Target alzato | 294 → 298 | 208.5 |
| 2026-04-30 16:23 | Morgan Stanley | Target alzato | 270 → 278 | 212.145 |
Ancora nulla